EXEL - Exelixis: Patent Woes And Challenging Market Dynamics Make For A Testy 2024

2024-03-28 14:54:46 ET

Summary

• Exelixis has seen strong revenue growth from its drug cabozantinib, but its net income has been inconsistent.
• The company is facing patent challenges from generics, with the potential for a generic version of cabozantinib to launch in 2026.
• Exelixis is working on developing a next-generation oral TKI, zanzalintinib, to replace cabozantinib, but its success is uncertain.

Investment Overview

I last covered Exelixis ( EXEL ) in a note for Seeking Alpha back in August 2023. The company markets and sells cabozantinib, which it describes as follows in its 2023 annual report/10K submission:

Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been approved by the U.S. Food and Drug Administration (FDA) and in 69 other countries: as CABOMETYX® (cabozantinib) tablets for advanced renal cell carcinoma ("RCC") (both alone and in combination with Bristol-Myers Squibb Company’s ( BMY ) nivolumab (OPDIVO®)), for previously treated hepatocellular carcinoma ("HCC") and for previously treated, radioactive iodine ("RAI")-refractory differentiated thyroid cancer ((DTC)); and as COMETRIQ® (cabozantinib) capsules for progressive, metastatic medullary thyroid cancer ((MTC)).

For further details see: